Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

[1]  Z. Estrov,et al.  Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jeffrey A Jones,et al.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[3]  E. Kimby,et al.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? , 2014, Blood.

[4]  J. Byrd,et al.  Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant , 2014 .

[5]  J. Byrd,et al.  Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Ulrich,et al.  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.

[7]  T. Kipps,et al.  ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control. , 2014 .

[8]  M. Görner,et al.  The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[10]  N. Schmitz,et al.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. , 2013, Blood.

[11]  R. Benjamin,et al.  Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia , 2013, British journal of haematology.

[12]  B. Narasimhan,et al.  Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia , 2013, Leukemia.

[13]  D. Blaise,et al.  Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. , 2013, Experimental hematology.

[14]  J. Gribben,et al.  Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome , 2012, Leukemia.

[15]  Sebastian Böttcher,et al.  Flow cytometric MRD detection in selected mature B-cell malignancies. , 2013, Methods in molecular biology.

[16]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[17]  J. Pinilla-Ibarz,et al.  Treatment of relapsed or refractory chronic lymphocytic leukemia. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[18]  C. Bueso-Ramos,et al.  Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia , 2011, Cancer.

[19]  N. Schmitz,et al.  Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. , 2010, Blood.

[20]  N. Kröger,et al.  Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Döhner,et al.  Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis , 2009, Leukemia.

[23]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[24]  F. Patriarca,et al.  Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation , 2009, Haematologica.

[25]  N. Schmitz,et al.  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Einsele,et al.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.

[28]  N. Schmitz,et al.  Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial , 2008, Leukemia.

[29]  N. Schmitz,et al.  Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis. , 2007 .

[30]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[31]  E. Kimby,et al.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.

[32]  E. Giné,et al.  Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. , 2005, Blood.

[33]  J. Lipton,et al.  Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease , 2005, Bone Marrow Transplantation.

[34]  R. Brand,et al.  Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis , 2005, Leukemia.

[35]  W. Siegert,et al.  Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Montserrat,et al.  Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia , 2002, Leukemia.

[37]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.